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Abstract: SARS-CoV-2 has caused a pandemic coronavirus disease 2019 (COVID-19), claiming over a
million worldwide lives of people among whom those with cardiovascular disease or hypertension are
over-represented. Understanding the mechanism by which coronavirus threatens human health is vital
for reducing the current disease burden and even for preventing future attacks. Inspired by the temporal
relationship between three coronavirus outbreaks in humans since 2000 and hypertension medications
gaining popularity since 2000, we discuss here how hypertension medications might contribute to the
COVID-19 pandemic and mortality with a focus on inhibitors of the renin-angiotensin-aldosterone system
(RAAS). The fact that RAAS inhibitors increase angiotensin converting enzyme-2 (ACE2) expression in
respiratory epithelial cells, the kidneys and heart has stirred a surge of interest in the discussion of the
role of RAAS inhibitors in COVID-19 disease, all related to ACE2-mediated effects [1–5]. Here, we
abstain from contributing further to this extensive discussion, but expand this discussion beyond ACE2
and centre on how RAAS blockade influences human interaction with SARS-CoV-2 by altering acid-base
balance. This expansion is based on our previous experimental work conducted on aldosterone deficient
mice [6] and on the fact, supported by accumulated groundwork in physiology, that acid-base homeostasis
is maintained by the coordinated work of kidneys and lungs, and is vital for normal physiology and health.
RAAS evolved to facilitate humans’ adaptation to land life by conserving salt and water in the intestine
and kidney, and facilitating renal acid and other water-soluble waste elimination. As renal acid-excretion
effects are largely dependent on the RAAS, inhibiting renal salt absorption by RAAS inhibitors in attempt
to reduce blood pressure also slows renal acid elimination (see fig. 1 below).
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SARS-CoV-2 has caused a pandemic coronavirus disease
2019 (COVID-19), claiming over a million worldwide
lives of people among whom those with cardiovascular
disease or hypertension are over-represented. Understand-
ing the mechanism by which coronavirus threatens human
health is vital for reducing the current disease burden and
even for preventing future attacks. Inspired by the temporal
relationship between three coronavirus outbreaks in hu-
mans since 2000 and hypertension medications gaining
popularity since 2000, we discuss here how hypertension
medications might contribute to the COVID-19 pandemic
and mortality with a focus on inhibitors of the renin-an-
giotensin-aldosterone system (RAAS). The fact that RAAS
inhibitors increase angiotensin converting enzyme-2
(ACE2) expression in respiratory epithelial cells, the kid-
neys and heart has stirred a surge of interest in the dis-
cussion of the role of RAAS inhibitors in COVID-19 dis-
ease, all related to ACE2-mediated effects [1–5]. Here, we
abstain from contributing further to this extensive discus-
sion, but expand this discussion beyond ACE2 and centre
on how RAAS blockade influences human interaction with
SARS-CoV-2 by altering acid-base balance. This expan-
sion is based on our previous experimental work conducted
on aldosterone deficient mice [6] and on the fact, support-
ed by accumulated groundwork in physiology, that acid-
base homeostasis is maintained by the coordinated work
of kidneys and lungs, and is vital for normal physiology
and health. RAAS evolved to facilitate humans’ adaptation
to land life by conserving salt and water in the intestine
and kidney, and facilitating renal acid and other water-sol-
uble waste elimination. As renal acid-excretion effects are
largely dependent on the RAAS, inhibiting renal salt ab-
sorption by RAAS inhibitors in attempt to reduce blood
pressure also slows renal acid elimination (see fig. 1 be-
low).
Hypertension and COVID-19 mortality
The Chinese Centre for Disease Control and Prevention
reported that the highest mortality rate (10.5%) of
COVID-19 was in people with cardiovascular disease, fol-
lowed by diabetes, chronic respiratory disease, hyperten-
sion and cancer, whereas the overall mortality rate was
2.3% in a sample of nearly 50,000 patients [7–9]. Among
conditions classified as “cardiovascular disease” the most
common is hypertension. Subsequently, several indepen-
dent studies from China, Italy and Spain found that up to
80% of COVID-19 mortality cases have arterial hyperten-
sion and 30% have type 2 diabetes [10, 11]. According
to the American College of Cardiology and the American
Heart association some 46% of American adults have high
blood pressure, as defined by the College standards (>130/
80 mm Hg) [12].
Hypertension, unless it is a hypertensive crisis, does not
exert a negative influence on lung tissues or on lung func-
tion. Therefore, patients with hypertension should not have
been exceptionally susceptible to SARS-CoV-2 infection
and its consequences, unless they have accompanying lung
disease or generally lower immunity [13]. On the other
hand, the commonality in patients with cardiovascular dis-
ease and/or diabetes and/or hypertension is treatment with
angiotensin-converting enzyme inhibitors (ACEIs) or an-
giotensin-II receptor blockers (ARBs) as they have been
shown to be cardio- and renal protective in clinical trials
[14, 15]. Wu and McGooan’s findings suggested a link be-
tween ACEI and ARB use and increased case fatality [7].
Mechanism linking hypertension medication to
COVID-19 infectivity and pandemic
SARS-CoV-2 is transmitted mainly through the respiratory
route and specifically uses its surface spike protein to gain
entry into respiratory epithelial cells via binding to ACE2
[16], in the same way as SARS-CoV [17]. The crucial role
of ACE2 in mediating SARS-CoV infection was demon-
strated previously in a study where knockout of ACE2
granted the mice resistance to SARS-CoV infection, virus
replication and the subsequent inflammatory cell infiltra-
tions in their lungs [18]. Similarly, in human lung tissue,
SARS-CoV infection depends on ACE2 protein expression
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levels. The well-differentiated ciliated cells with the most
abundant ACE2 protein expression on the apical surface
are the main entry and infection site for SARS-CoV [19].
SARS-CoV-2 virus has binding affinity to ACE2 ~10- to
20-fold higher than SARS-CoV [17]. This suggests the
greater ACE2 protein expression levels in the respiratory
epithelium and the high level of ventilation should define
one’s propensity to and the severity of SARS-CoV-2 in-
fection. Common anti-hypertension medications targeting
the RAAS – ACEIs and ARBs – upregulate ACE2 ex-
pression in lung, heart and kidney [20, 21]. They also re-
duce glomerular filtration rate, aldosterone synthesis and
renal bicarbonate reabsorption in several animal models
[22]. Mineralocorticoid receptor blockers used in conges-
tive heart failure also have ACE2-upregulating effects [23]
and directly block aldosterone’s acid-excreting action in
the renal tubules. By compromising renal acid excretion,
RAAS inhibitors expand the baseline body acid pool and
consume pH-buffering components, of which the prime
one in the blood is the bicarbonate of the bicarbonate / car-
bonic acid buffer system. This makes the body prone to
pH fluctuations and to the sudden rises in pCO2, which de-
mand reflexive increases in ventilation to maintain acid-
base balance [6, 24]. RAAS inhibitors therefore may fur-
ther facilitate interaction of SARS-CoV-2 with our
respiratory system by increasing ventilation if the bicar-
bonate level is low enough to cause pH drops during activ-
ities. Moreover, the burdening effect of insufficient renal
acid elimination on the cardiorespiratory system is mag-
nified when the body is in a hypermetabolic state, where
body CO2 production is massively increased, such as in
chronic heart and respiratory disease and cancer [6].
Chronic heart and respiratory disease and cancer them-
selves contribute to COVID-19 infection mortality [7].
Mechanism linking hypertension medication to
COVID-19 mortality
Developing acid-base imbalance
ACEIs and ARBs use should also prime patients to de-
velop metabolic acidosis during SARS-CoV-2 infection
because of a further increase in ventilation to overcome
ventilation/perfusion mismatch and a sudden increase in
endogenous acid production from acute inflammatory
processes. Peripheral tissue inflammation is characterised
by tissue hypoxia due to small vessel damage, and ac-
tivation and infiltration of innate immune cells, together
with clonal expansion of adaptive immune cells. All these
processes contribute to local pH reduction, which can be as
low as 5.5 [25]. Activated neutrophils and T lymphocytes
rely mainly on glycolytic metabolism for proliferation, dif-
ferentiation and function, which results in accumulation of
lactic acid [26]. Analogous to this scenario, insufficient re-
nal acid elimination due to the use of ACEIs was reported
to induce metabolic acidosis during surgical stress [27].
Metabolic acidosis compromising cell-mediated immu-
nity
Once metabolic acidosis has developed, extracellular aci-
dosis impairs cellular immunity, which plays a vital role in
the clearance of SARS-CoV-2 and other respiratory virus-
es [28].
Pulmonary cytotoxic CD8 T cells recognise and induce
apoptosis in virus-infected cells through direct (cell-cell
contact) and indirect mechanisms with the involvement
of secreted cytolytic enzymes perforin and granzymes, as
well as the cytokines interferon-γ and tumour necrosis fac-
tor [28]. A subpopulation of CD4 T cells is also recruited
in parallel, and differentiate into cytotoxic T cells which
further expands CD8 T cell pool. Some CD8 cells are even
stimulated to gain the memory of CD8 T cell phenotype.
Transient increases in both effector and memory CD8 T
cells constitutes an effective and efficient response during
early viral infection [29]. Low pH has been shown to in-
duce anergy in CD8 T cells, including reduced cell prolif-
eration, cytokine production, and impaired cytotoxic activ-
ity [30, 31]. It also suppresses natural killer (NK) and NKT
cells to produce cytotoxic responses and interferon-γ [32,
33] and inhibits CD4+ T cell function [34]. Acidosis also
increases circulating glucocorticoid levels. Its anti-inflam-
matory and immunosuppressive properties further com-
promise immunity against viruses [35, 36]. Lymphopenia,
which can be induced by acute metabolic acidosis [37] was
reported to predict disease severity and secondary bacteri-
al infection in COVID-19 [8, 38]. Without robust cellular
immune responses to clear virus efficiently, evolving host
tissue destruction during uncontrolled viral infection elicits
persistent innately induced inflammation likely to predis-
pose to the development of cytokine storm, which acceler-
ates the progression to lung failure [39, 40]. Prolonged cy-
totoxic T cell activity in the lung and other tissues in this
scenario exacerbates organ damage by exaggerating im-
munopathology.
SARS-CoV-2 infection also can cause a coagulopathy, al-
ready seen in the early phase, and it has been suggested
that this is a result of accumulated proinflammatory re-
sponses [41]. Extracellular acidosis selectively dampens
homeostatic functions while increasing the pro-inflamma-
tory effects of platelets [42]. It is plausible that dysfunc-
tional platelets caused by acidosis contribute to
COVID-19–associated coagulopathy.
Added to RAAS blockade that compromises cellular im-
munity via acidosis, ACEIs may further spread viral repli-
cation and invasion by inhibiting the antigen processing
and presentation that are essential to facilitate and enhance
adaptive immunity. Intracellular ACE enzymatically pre-
pares self and non-self major histocompatibility complex
(MHC) class 1 peptides to be presented onto the surface of
virus-infected cells [43]. The catalytic activity of ACE in
monocytes and macrophages is also required during their
antigen processing and presentation processes [43].
Figures 1 and 2 graphically illustrate the above mechanis-
tic links.
Discussion
Coronaviruses have insidiously become human threats
since 2000 [44]. Three outbreaks in sequence – severe
acute respiratory syndrome (SARS) in 2002, Middle East
respiratory syndrome in 2012, and 2020 COVID-19, tem-
porally coincide with hypertension medications gaining
popularity [45, 46]. ACEIs and ARBs have stood out
among all types of antihypertensive medications as guide-
line-recommended first line therapy in diabetic hyperten-
sion [47, 48] and in secondary prevention for acute coro-
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nary syndromes. ACEIs and ARBs potentially attenuate
cardiovascular and renal function decline, particularly in
diabetic patients [14, 15], but they may cause humans
to gradually lose anti-coronavirus immunity by increasing
ACE2 expression and precipitating the development of
metabolic acidosis, which compromises cell-mediated im-
munity. The RAAS evolved to facilitate adaptation of ter-
restrial vertebrates including humans, to land life by con-
serving salt and water in the intestine and kidney, and
facilitating renal acid and other water-soluble waste elim-
ination. Blocking the RAAS’s ability to retain sodium in
the kidney to reduce blood pressure also reduces renal
ability to excrete acidic waste [49]. This primes the de-
velopment of full-blown metabolic acidosis during acute
stress, such as infection as is the case in COVID-19 dis-
ease. Long-term ACEI/ARB use was recently reported to
correlate with severe renal dysfunction and acute kidney
injury in patients with severe COVID-19 [50]. Low serum
bicarbonate levels in both hospitalised patients (<22 mEq/
l) and in non-hospitalised patients (<24 mEq/l) carried high
risks of acute kidney injury [51]. Metabolic acidosis con-
tributes to acute kidney injury via intrarenal RAAS activa-
tion, renal tubular inflammation and ischaemic injury [52,
53]. All these findings together support our hypothesis that
ACEIs/ARBs contribute to COVID-19 disease by predis-
posing their users to the development of metabolic acidosis
during infection. Our hypothesis is based on our own ex-
perimental results in animals with complete lack of aldos-
terone. Therapeutic dysregulation of aldostereone levels by
ACEIs/ARBs in human patients may have only partial ef-
fects on the development of metabolic acidosis.
There has been growing interest in the mechanistic link be-
tween up-regulation of ACE2 by ACEIs and ARBs, and
acute lung failure in COVID-19 [1–3, 5, 54]. Several
groups specifically propose that, by increasing ACE2 lev-
els, ACEIs and ARBs should protect against the acute pro-
gression to lung failure in SARS-CoV-2 infection [2, 4,
54]. Their proposition is rooted in the finding by Lami
et al. that ACE2 knockout mice were more susceptible to
acute lung failure induced by acid aspiration or sepsis sec-
ondary to caecal ligation and perforation [55]. Also, ele-
vated ACE2 levels could attenuate the pulmonary vaso-
constrictive and inflammatory effects of angiotensin II, the
level of which is positively related to SARS-CoV-2 viral
load and lung injury [54]. Indeed, perturbing or downreg-
ulating ACE2 induces uncontrolled inflammation in hosts.
This is the common mechanism employed by respiratory
syncytial virus, influenza virus and SARS-CoV [55, 56].
But it also has to be emphasised here that downregulation
of ACE2 protein expression in SARS-CoV infection is ini-
tiated by the binding of the surface spike protein of SARS-
CoV virus to ACE2 [18]. That also means that ACE2 re-
duction is the direct consequence of the ACE2-mediaed
entry by SARS-CoV virus. This sequential mechanistic
link explains why ACE2 knockout mice have protection
rather than susceptibility to SARS-CoV-induced lung fail-
ure, as mentioned in the previous paragraph [55]. It there-
fore has to be made clear that in the case of SARS-CoV
infectious diseases, the high ACE2 expression in respira-
tory epithelium does not confer protection and enhances
the virus entry. The idea of keeping ACE2 levels high
after SARS-CoV-2 infection, in order to moderate virus-
induced lung injury and slow the disease progression to
lung failure, is not new. Sodhi et al. have demonstrated that
recombinant ACE2 benefits bacterially infected lungs af-
ter an initial inflammatory response [57]. Though ACEIs
Figure 1: Influence of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II receptor blockers (ARBs) used as hyper-
tension medication on acid-base balance regulation. Blocking the renin-angiotensin-aldosterone system with ACEIs or ARBs reduces re-
nal acid elimination, leading to constant activation of brainstem-mediated chemoreceptor reflex to increase acid elimination by ventilation and
burdens cardiopulmonary system. (Figure modified from Liao et al. [6])
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and ARBs could also increase pulmonary ACE2 protein
level expression, the cost of accompanying increases in
cardiopulmonary burden, the respiratory tract interaction
with SARS-CoV-2, and the predisposition to the develop-
ment of metabolic acidosis during stress should outweigh
the potential benefits. On the other hand, Teijaro et al. re-
vealed that pulmonary endothelial cells are a key regula-
tor of cytokine storm development during influenza virus
infection. They even demonstrated that pharmacological-
ly manipulating the sphingosine-1-phosphate receptor sig-
nalling successfully inhibits cytokine storm, but it does not
affect virus clearance [39]. Before the emergence of effec-
tive therapy against SARS-CoV-2 virus, pharmacological
alteration of sphingosine-1-phosphate receptor signalling
may ameliorate the lung injury caused by cytokine storm.
In the meantime, several retrospective clinical studies have
shown that the use of ACEIs and ARBs does not affect
SARS-CoV-2 infection [11, 58, 59]. We would like to draw
attention to the limitations of their levels of evidence and
study design. Case-control studies have an evidence lev-
el of hypothesis generation only, not of theory. Post-hoc
analysis is even more problematic. The chosen statistical
methods and surrogate outcome measures all can produce
biases. The method of conditional logistic regression used
in two [11, 59] and “propensity score matching” used in
one retrospective clinical study [58] are intended to cir-
cumvent confounding bias. No one can balance un-recog-
nised causal factors. Propensity score matching has been
criticised [60] because it has the bias of treating all recog-
nised confounders as categorical irrespective of their na-
ture. Confounders are not always categorical like sex or
ethnicity. Those that also have continuous components,
such as quantities of alcohol, betel nut, cigarette use, di-
et, medication, exposure length and the dose greatly in-
fluence their effects. Propensity score matching, however,
is unable to take the dose and exposure length into ac-
count because it reduces all confounders to presence or
absence. This is also true for certain diseases. Ten years
on an ACEI, for example lisinopril 10 mg once daily,
should be different from another kind of ACEI, for ex-
Figure 2: Influence of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II receptor blockers (ARBs) used as hyper-
tension medication on increased susceptibility to and mortality in SARS-CoV-2 infection. (1) Blocking renin-angiotensin-aldosterone
system with ACEIs or ARBs reduces renal acid elimination, leading to increased ventilation to maintain acid-base balance. This process also
(2) increases opportunity for SARS-CoV-2 to interact with respiratory system and (3) increases angiotensin-converting enzyme 2 (ACE2) ex-
pression in respiratory epithelial cells, the target of SARS-CoV-2 to gain access to our body. (4) Inflammatory responses in the respiratory sys-
tem aiming to eliminate SARS-CoV-2 result in generation of more acidic metabolic wastes, which together with increased respiratory muscular
work leads to the development of metabolic acidosis. (5) Metabolic acidosis compromises adaptive cellular immunity and (6) inefficient eradi-
cation of SARS-CoV-2 may predispose to the generation of cytokine storm.
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ample enalapril 10 mg twice daily only for 3 months, in
terms of aldosterone-inhibitory and acid-retaining effects,
and effects on ACE2 expression in the respiratory epithe-
lial cells. In the efficiency of lung eliminating CO2 waste,
total respiratory tract surface area also varies between a pa-
tient with chronic lung disease for 1 year and another for
10 years. Propensity score matching also does not take in-
to account disease-disease interactions and drug-drug in-
teractions. Many medications have been reported to alter
acid-base balance [61]. One obvious example is bicarbon-
ate supplementation used to retard chronic kidney disease
progression. The bicarbonate supplementation should neu-
tralise the acidosis triggered by ACEIs and ARBs. More-
over, drugs and diseases may also interact synergistically
or additively and modify the disease outcomes, which nei-
ther propensity score matching nor logistic regression can
reveal. Furthermore, the outcomes used in these studies are
not objective, such as “admission” or “not admission” to
the hospital [11] or to the intensive care unit (ICU), and
non-invasive ventilator use or not, as indicators of disease
severity [58]. All these interventions are not double-blind-
ed and are subjected to the doctors’ choices and the avail-
able resources. Hospitals in different regions and at differ-
ent time-points of the COVID-19 pandemic differ in the
availability and abundance of medical supplies, ICU beds
and ICU specialists. Lastly, the study design and statisti-
cal analysis should be considered. A non-inferiority design
should be used to test an alternative hypothesis (H1) to
prove the safety of an intervention, instead of a superiori-
ty design and null hypothesis (H0) testing. The main con-
cern brought up about RAAS inhibitors in COVID-19 was
that these inhibitors increase COVID-19 risk by increas-
ing ACE2 expression. Therefore, for a clinical study chal-
lenging this hypothesis, its statistical analysis should be a
non-inferiority test. But all studies discussed here used the
superiority test with the null hypothesis being that RAAS
inhibitors do not increase COVID-19 risks. To falsify the
hypothesis of RAAS inhibitors increasing COVID-19 risk,
the clinical study should have a null hypothesis “RAAS in-
hibitors increase COVID-19 risk”. Even with these pitfalls
the study by de Abajo et al. [11] showed that patients with-
out use of any antihypertensive drugs are better off (odds
ration [OR] ~0.5) for COVID-19 requiring hospital admis-
sion than RAAS inhibitor users (OR ~0.9–1.1, tables 2 and
3 in the original article), irrespective of comparisons with
patients on other medications. This finding may be due
to the fact that nearly all currently available antihyperten-
sive medications inhibit renal acid excretion to some ex-
tent [61] with ACEIs, ARBs and mineralocorticoid antag-
onists directly targeting aldosterone, the final downstream
effector of the RAAS, which has powerful stimulating ef-
fects on renal acid excretion in the form of ammonium and
through urinary acidification. With the inherent pitfalls in
retrospective clinical studies, their conclusion of no asso-
ciation between the use of ACEIs and ARBs and SARS-
CoV-2 infection probability and outcomes can only be
viewed as hypothesis-generating and not theory-forming.
Randomised clinical trials with all confounders equalised
prior to the study are warranted to elucidate whether
RAAS inhibitors contribute to COVID-19 disease.
Conclusion
To find the true role of RAAS inhibitors in COVID-19,
explanatory mechanisms and evidence of outcome mod-
ifications from clinical studies should both be provided.
Our work explains mechanisms by which RAAS inhibitors
may increase susceptibility to and the development of cy-
tokine storm during SARS-CoV-2 infection. These mech-
anistic links are supported by our previous work in al-
dosterone deficient mice and accumulated groundwork in
physiology in the field of acid-base balance. Our work ap-
pears to support the suggestion that patients on ACEIs and
ARBs for hypertension control during COVID infection
should be switched to other types of antihypertensive med-
ication [3]. This would potentially reduce the interaction
of our respiratory tract with SARS-CoV-2 and lower the
viral loads. Moreover, by resuming renal elimination of
acidic wastes, it would relieve the cardiopulmonary bur-
den of SARS-CoV-2-infected patients. A L-type calcium
channel blocker, amlodipine for example, may be a bet-
ter choice because it has minimal effects on RAAS inhi-
bition [62]. Calcium channel blockers have varying/incon-
sistent effects on the RAAS [63], as medications in ACEI
and ARB groups have on increasing ACE2 levels in dif-
ferent disease backgrounds. However, because our work
is not yet backed up by clinical data to demonstrate that
RAAS inhibitors alter COVID-19 infectivity and disease
outcome by predisposing the development of acidosis dur-
ing infection, it should only be treated as hypothesis-gen-
erating but not theory-forming. Therefore, it is not advised
to be used as a sole guide to the treatments currently. Given
the complexity of human physiology and pathophysiology,
the precise understanding of how ACEIs and ARBs influ-
ence the relationship with and immune response to SARS-
CoV-2 virus in humans warrants well-planned randomised
clinical trials. Several professional societies have recom-
mended continuing ACEIs and ARBs as prescribed, fol-
lowing the mainstream guidelines [64]. With this work, we
suggest that in future clinical studies planned to address the
role of RAAS inhibitors in COVID-19, data including ar-
terial blood gases, potassium levels, the amount of bicar-
bonate use and even renal replacement therapy use in the
patients should also be collected, as these data analysed all
together help the patient outcome assessment and also im-
prove understanding of the effects of RAAS inhibition on
COVID-19 disease.
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